Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer

被引：27
作者：
Choughule, A. [1 ]
Sharma, R. [1 ,2 ]
Trivedi, V. [1 ,2 ]
Thavamani, A. [1 ,2 ]
Noronha, V. [1 ]
Joshi, A. [1 ]
Desai, S. [3 ]
Chandrani, P. [2 ]
Sundaram, P. [2 ]
Utture, S. [1 ]
Jambhekar, N. [3 ]
Gupta, S. [1 ]
Aich, J. [2 ]
Prabhash, K. [1 ]
Dutt, A. [2 ]
机构：
[1] Tata Mem Hosp, Tata Mem Ctr, Dept Med Oncol, Bombay 400012, Maharashtra, India
[2] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Navi Mumbai, India
[3] Tata Mem Hosp, Tata Mem Ctr, Dept Pathol, Bombay 400012, Maharashtra, India
来源：
BRITISH JOURNAL OF CANCER | 2014年 / 111卷 / 11期
基金：
英国惠康基金;
关键词：
GROWTH-FACTOR-RECEPTOR; GEFITINIB; THERAPY; GENE; ERLOTINIB; SURVIVAL; FEATURES;
D O I：
10.1038/bjc.2014.401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2203 / 2204
页数：4
相关论文
共 19 条
  • [1] [Anonymous], P AM SOC CLIN S623S
  • [2] Benesova L, 2010, ANTICANCER RES, V30, P1667
  • [3] Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity
    Chougule, Anuradha
    Prabhash, Kumar
    Noronha, Vanita
    Joshi, Amit
    Thavamani, Abhishek
    Chandrani, Pratik
    Upadhyay, Pawan
    Utture, Sagarika
    Desai, Saral
    Jambhekar, Nirmala
    Dutt, Amit
    [J]. PLOS ONE, 2013, 8 (10):
  • [4] Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
    Fukuoka, Masahiro
    Wu, Yi-Long
    Thongprasert, Sumitra
    Sunpaweravong, Patrapim
    Leong, Swan-Swan
    Sriuranpong, Virote
    Chao, Tsu-Yi
    Nakagawa, Kazuhiko
    Chu, Da-Tong
    Saijo, Nagahiro
    Duffield, Emma L.
    Rukazenkov, Yuri
    Speake, Georgina
    Jiang, Haiyi
    Armour, Alison A.
    To, Ka-Fai
    Yang, James Chih-Hsin
    Mok, Tony S. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) : 2866 - 2874
  • [5] Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
    Ihle, Nathan T.
    Byers, Lauren A.
    Kim, Edward S.
    Saintigny, Pierre
    Lee, J. Jack
    Blumenschein, George R.
    Tsao, Anne
    Liu, Suyu
    Larsen, Jill E.
    Wang, Jing
    Diao, Lixia
    Coombes, Kevin R.
    Chen, Lu
    Zhang, Shuxing
    Abdelmelek, Mena F.
    Tang, Ximing
    Papadimitrakopoulou, Vassiliki
    Minna, John D.
    Lippman, Scott M.
    Hong, Waun K.
    Herbst, Roy S.
    Wistuba, Ignacio I.
    Heymach, John V.
    Powis, Garth
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (03): : 228 - 239
  • [6] Mutations of the epidermal growth factor receptor gene in lung cancer:: Biological and clinical implications
    Kosaka, T
    Yatabe, Y
    Endoh, H
    Kuwano, H
    Takahashi, T
    Mitsudomi, T
    [J]. CANCER RESEARCH, 2004, 64 (24) : 8919 - 8923
  • [7] Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts
    Li, S.
    Li, L.
    Zhu, Y.
    Huang, C.
    Qin, Y.
    Liu, H.
    Ren-Heidenreich, L.
    Shi, B.
    Ren, H.
    Chu, X.
    Kang, J.
    Wang, W.
    Xu, J.
    Tang, K.
    Yang, H.
    Zheng, Y.
    He, J.
    Yu, G.
    Liang, N.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 110 (11) : 2812 - 2820
  • [8] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Lièvre, A
    Bachet, JB
    Le Corre, D
    Boige, V
    Landi, B
    Emile, JF
    Côté, JF
    Tomasic, G
    Penna, C
    Ducreux, M
    Rougier, P
    Penault-Llorca, F
    Laurent-Puig, P
    [J]. CANCER RESEARCH, 2006, 66 (08) : 3992 - 3995
  • [9] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Lynch, TJ
    Bell, DW
    Sordella, R
    Gurubhagavatula, S
    Okimoto, RA
    Brannigan, BW
    Harris, PL
    Haserlat, SM
    Supko, JG
    Haluska, FG
    Louis, DN
    Christiani, DC
    Settleman, J
    Haber, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2129 - 2139
  • [10] KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
    Mao, Chen
    Qiu, Li-Xin
    Liao, Ru-Yan
    Du, Fang-Bing
    Ding, Hong
    Yang, Wan-Chun
    Li, Jin
    Chen, Qing
    [J]. LUNG CANCER, 2010, 69 (03) : 272 - 278
12